AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given a consensus recommendation of “Buy” by the ten research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $89.75.
Several research analysts recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th.
Get Our Latest Stock Analysis on AstraZeneca
Hedge Funds Weigh In On AstraZeneca
AstraZeneca Stock Down 0.5 %
AZN opened at $66.60 on Tuesday. The stock has a market capitalization of $206.50 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a 50-day moving average of $66.11 and a two-hundred day moving average of $74.46.
AstraZeneca (NASDAQ:AZN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 earnings per share. On average, research analysts expect that AstraZeneca will post 4.11 earnings per share for the current year.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
- Five stocks we like better than AstraZeneca
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- When to Sell a Stock for Profit or Loss
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to Calculate Options Profits
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.